Novavax reported $216.06M in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Adma Biologics ADMA:US $ -13.22M 1.62M
Agenus AGEN:US $ -34.34M 20.08M
AstraZeneca AZN:LN 3562M 625M
Astrazeneca AZN:US $ 3562M 625M
Dynavax Technologies DVAX:US $ 128.77M 96.32M
Genocea Biosciences GNCA:US $ -15.37M 2.37M
Geron GERN:US $ -28.62M 2.3M
GlaxoSmithKline GSK:LN 2447M 673M
Mannkind MNKD:US $ -21.92M 2.4M
Minerva Neurosciences NERV:US $ -7.99M 13.39M
Moderna Inc MRNA:US 2.52B 1.78B
Novartis NVS:US $ 4660M 108M
Pain Therapeutics PTIE:US $ -17.51M 3.38M
Peregrine Pharmaceuticals PPHM:US $ 2.49M 1.8M
Pfizer PFE:US $ 12921M 1739M
Sarepta Therapeutics SRPT:US $ -201.24M 125.08M